Despite the tremendous advances in the treatment of childhood kidney tumors, there remain subsets of pediatric renal tumors that continue to pose a therapeutic challenge, mainly malignant rhabdoid kidney tumors and non-osseous renal Ewing sarcoma.
Author Manuscript Published OnlineFirst on January 24, 2014; DOI: 10.1158/1541-7786.MCR- Significant improvements in the outcome of children with renal malignancies have been achieved over the last 20 years. Advances in medical and surgical care, and the use of cooperative trials have resulted in five year survival rates for Wilms tumor that exceed 90% [1] . There remain, however, subsets of pediatric solid renal tumors that have not recognized a significant improvement in survival. These tumors include malignant rhabdoid kidney tumors and renal Ewing sarcomas. Malignant rhabdoid kidney tumors (MRKT) are aggressive malignancies that comprise 2% of all pediatric renal tumors [2] . Children diagnosed with these tumors often have metastatic disease [2, 3] and despite aggressive treatment, their overall survival rate is less than 30% [2] .
Solid organ sarcomas such as extra-osseous renal Ewing sarcomas are also rare and difficult pediatric kidney tumors [4] with a 5-year disease free survival rate less than 50% [5] .
Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase that localizes to focal adhesions and controls a number of cellular pathways involved in cell adhesion, migration, invasion, proliferation, and survival [6] [7] [8] [9] . FAK activation occurs when cell surface integrins bind to β subunits of FAK, resulting in phosphorylation and binding of Src family kinases [6] . FAK also has an autophosphorylation site at the tyrosine 397 (Y397) residue [10] which leads to increased cell survival via inhibition of detachmentactivated apoptosis, or anoikis [11] . FAK is overexpressed in many human adult tumors, including breast and colon cancer [12] as well as the pediatric tumor, neuroblastoma [13] . FAK inhibition with small interfering RNA (siRNA) [14, 15] migration, invasion and survival. Abrogation of FAK phosphorylation at this site using dominant negative constructs [16] and small molecule inhibitors [15, [17] [18] [19] , has been shown to decreased tumor cellular migration, invasion, and survival.
In the current study, we hypothesized that rare pediatric renal tumors would express FAK, and that inhibition of FAK would result in a less aggressive phenotype in these cell lines. We demonstrated that abrogation of FAK in renal tumor cell lines resulted in decreased tumor cell survival in vitro and decreased xenograft growth in vivo. From these studies, we concluded that targeting FAK may prove to be a useful therapeutic modality in the treatment of these rare, but aggressive, pediatric renal tumors.
Methods
Cells and Cell Culture -The renal tumor cell lines G401 and SK-NEP-1 were utilized.
The malignant rhabdoid kidney tumor cell line, G401 [20] , (CRL-1441, American Type Culture Collection, ATCC, Manassas, VA) was maintained in McCoy's medium , ATCC) containing 10% non-heat-inactivated fetal bovine serum (Hyclone, Suwanee, GA), 1 μg/mL penicillin (Gibco, Carlsbad, CA), 1 μg/mL streptomycin (Gibco), and 2 mM L-glutamine (Thermo Fisher Scientific Inc., Waltham, MA) at 37 ºC and 5% CO 2 . SK-NEP-1 cells, previously described as a renal Ewing's sarcoma [21] , were obtained from ATCC (HTB-48,) and maintained in McCoy's medium (ATCC) containing 15% fetal bovine serum (Hyclone), 1 μg/mL penicillin / streptomycin and 2 mM Lglutamine (Thermo Fisher Scientific) at 37 ºC and 5% CO 2 for FAK detection and were a kind gift from Dr. Elena Kurenova [22] . They were maintained under standard conditions in Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum, 2 mM L-glutamine and 1 µg/mL penicillin / streptomycin. Human Tissue Specimens -Formalin-fixed, paraffin-embedded pediatric renal tumor specimens were obtained under waiver of informed consent from the tumor repository at our institution and from the Children's Oncology Group after institutional review board approval (X111123007).
Antibodies and Reagents
Immunohistochemistry -Formalin-fixed paraffin-embedded human tumor or xenograft tumor specimens were sectioned into 6 µM sections and baked at 70°C for one hour on Immunohistochemical Scoring -Stained slides of human tumors were reviewed and scored by a pediatric pathologist (E.M.M.) blinded to the patients. The staining was evaluated using a weighted stain score, that graded staining intensity (0, none; 1, weak; 2, moderate; 3, strong) and multiplied it by the percentage of tumor cells within each category. For example, if the specimen showed moderate staining (2) in 40% of the cells, the stain score would be 80 (2 × 40 = 80).
Immunoblotting -Western blots were performed as previously described [19] . Briefly, whole cell lysates or homogenized xenograft specimens were isolated using RIPA [10 mM Tris base pH 7.2, 150 mM NaCl, 1% Na-deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS)] or mTOR lysis buffers supplemented with protease treatment, either 10 μL of alamarBlue® dye (Invitrogen) was added and after 4-6 hours, the absorbance at 595 nm was measured using a kinetic microplate reader (BioTek Gen5, BioTek Instruments, Winooski, VT), or cell viability was determined using trypan blue exclusion and cell counting with a hemacytometer. Viability was reported as fold change.
Migration Assay -Twelve-well culture plates (TransWell®, Corning Inc., Lowell, MA) with 8 µm micropore inserts were used. The bottom side of the insert was coated with collagen Type I (10 mg/mL, 50 μL for 4 hours at 37 °C). G401 cells were treated with PF-573,228 or Y15 and were placed into the upper well at a concentration of 5 x 10 3 cells per well. Cells were allowed to migrate through the micropore insert for 24 hours. After two weeks, the animals were randomized and began twice daily treatments with intraperitoneal injection of either control vehicle (saline, 100 μL, n=7) or 1,2,4,5-benzenetetraamine tetrahydrochloride (Y15, 15 mg/kg, 100 μL, n=8). Previous experiments with various doses and dosing schedules of the compound proved this dosage to be well tolerated [19, 23] . After two weeks of treatment, the animals were euthanized with CO 2 and bilateral thoracotomy and the kidney tumors and lungs were harvested. Determination of Metastases -Three levels from each lung of the animals from the SK-NEP-1 xenografts (above) were formalin fixed (10% buffered formalin), paraffin embedded and stained by routine hematoxylin and eosin. Three levels from each lung were examined by a board certified pediatric pathologist (EMM) to determine the presence or absence of metastases.
Data Analysis -Experiments were repeated at least in triplicate, and data reported as mean ± standard error of the mean. Densitometry of western blots was performed using the image histogram analysis feature of Adobe Photoshop® software (Adobe Systems Inc., San Jose, CA). Student's t-test, Fisher's exact test, or ANOVA was used as appropriate to compare data between groups.
Statistical significance was determined at the p<0.05 level.
Results

Focal adhesion kinase (FAK) was present in pediatric renal tumor specimens and cell
lines. Immunohistochemistry was performed on 55 human pediatric renal tumor specimens, including 12 human malignant rhabdoid kidney tumor tissue specimens.
Other tumor types included Wilms tumor (19) , clear cell sarcoma (12) and mesoblastic nephroma (12) . FAK staining was detected in 75% of malignant rhabdoid kidney tumors, compared with 33% of clear cell sarcomas, 32% of Wilms tumors, and 8% of mesoblastic nephromas (Table 1 ). The number of MRKT specimens staining positive for FAK was significantly greater than those of Wilms tumor or mesoblastic nephroma (Table 1 (Table 1) . FAK was not phosphorylated in any of the mesoblastic nephroma specimens (Table 1) . Representative photomicrographs are presented in Figure 1A . There was weakly positive FAK staining in the normal kidney specimens (no tumor) localized to the renal tubules ( Figure 1A FAK also affects cellular migration and invasion [15, 25] ; therefore, we wished to determine if these entities would be affected by abrogation of FAK. Due to the nonadherent nature of the cell line, the SK-NEP-1 cells were not amenable to the Transwell® method of studying migration or invasion. G401 cells were treated with increasing concentrations of PF-573,228 and allowed to migrate through the micropore membrane.
There was a significant decrease in cellular migration following PF treatment ( Figure 3D ), and this decrease occurred at concentrations of PF below the calculated LD 50 . For invasion, G401 cells were treated with increasing concentrations of PF-573,228 and allowed to invade through a Matrigel™ layer. Similar to the migration findings, there was a significant decrease in cellular invasion following PF treatment in the G401 cells ( Figure 3E ), that again, occurred at concentrations below the calculated LD 50 . 
1,2,4,5-benzenetetraamine tetrahydrochloride (Y15) treatment inhibited FAK and led to
decreased cell survival. PF-573,228 was not formulated for use in vivo [24] and we wished to advance these studies to an animal model. Therefore, we chose to utilize 1,2,4,5-benzenetetraamine tetrahydrochloride (Y15), one of only a few small molecule FAK inhibitors that can be used in animals [18, 19] . Y15 has been previously described and was designed to inhibit Y397 phosphorylation of FAK [17] . Using immunoblotting, we showed that Y15 treatment resulted in decreased FAK phosphorylation in both the G401 and the SK-NEP-1 cell lines ( Figure 4A ). Next, we examined how Y15 treatment affected cell survival using alamarBlue® assays. Both G401 and SK-NEP-1 cell lines showed significantly decreased cell survival following treatment with Y15 ( Figure 4B ). To determine whether the two FAK inhibitors would have synergistic effects when used in combination, we performed alamarBlue® assays with the G401 and SK-NEP-1 cell lines following treatment with PF or Y15 alone and in combination (Supplemental Data, Figure 1 D, E) . The combination index was calculated using the method described by Chou [26] and was nearly one for both cell lines, indicating that these two inhibitors primarily had an additive effect rather than a synergistic effect on cell viability when utilized together (Supplemental Data, Figure 1 D, E) . Figure   6D . Densitometry was used to compare immunoblots from a number of xenograft specimens. Phosphorylated FAK was expressed as a ratio to total FAK for each blot and normalized to the β-actin for that blot, allowing for a comparison to be made between the saline treated and the Y15 treated tumors. There was a significant decrease in the FAK phosphorylation (Y397) in the tumors from the animals treated with Y15 ( Figure 6E ). Since these tumors are known to metastasize to the lungs, we also examined the lung tissue with H & E staining for the presence of metastases. There was no difference in the number of pulmonary metastases in the control versus the treated animals (3.3 ± 0.5 vs. 3.7 ± 0.4 metastases per slide, control vs. Y15, NS). 
Discussion
Pediatric renal tumors, other than Wilms tumor, continue to pose a therapeutic challenge, highlighting the need for novel therapies. In this study, we explored the role of FAK in the tumorigenesis of two types of aggressive pediatric renal tumors, malignant rhabdoid kidney tumor and renal Ewing sarcoma. The rationale for the study of FAK in these tumors was three-fold. First, FAK has been shown to play a key role in two other aggressive pediatric solid tumors, neuroblastoma [13, 15] and hepatoblastoma [23] . In neuroblastoma, FAK was important not only for cell survival [13, 28] , but also for development of metastases [15] . In hepatoblastoma, FAK inhibition resulted in decreased cell survival in vitro and decreased xenograft tumor growth in vivo [23] .
Second, FAK has been found to be upregulated in the adult renal tumor, renal cell carcinoma (RCC), an aggressive tumor with survival rates around 50%. Jenq and colleagues compared FAK mRNA abundance in a metastatic Caki-1 RCC cell line to that from normal human renal cortex epithelial cells and found that there was a twice as much FAK mRNA in the Caki-1 cell line [29] . Another group examined FAK phosphorylation at the Y861 site by immunohistochemistry in 57 human renal cell carcinoma specimens and noted staining in over 30% of the samples, and on multivariate analysis, there was a correlation between FAK phosphorylation and cancer specific survival [30] . In another study, decreased FAK activity resulted in decreased renal cell carcinoma cell proliferation and migration [31] . In addition, inhibition of FAK phosphorylation at Y397 in Caki and 786-0 RCC cell lines with the small molecule quinazoline (DZ-50) resulted in decreased viability, reduced adhesion, arrested cell cycle, and reduced metastatic potential in vivo [32] . Finally, multiple other kinases that Akt immunostaining [35] . FAK interacts with the Akt pathway to increase tumor cell migration in both breast and colorectal cancers [36, 37] . These previous studies prompted us to hypothesize that FAK would be important in aggressive pediatric renal tumors and supported the need to describe its role in these tumors.
In the current investigations, we reported that FAK was expressed in human pediatric renal tumor specimens, and was more prominent in tumor types that tended to be more aggressive. Our sample numbers were too small to use the FAK stain score as a disease prognosticator, and that was not the purpose of the current study. It was interesting to note, however, that the MRKT had a median stain score of 15 compared revealed that the characterization of FAK in pediatric renal tumors and cell lines has not been previously described.
The number of cell lines available for study of these rare, but deadly, pediatric renal tumors is limited. Both the G401 and SK-NEP-1 cell lines were originally thought to be Wilms tumor. The G401 cell line was characterized as a malignant rhabdoid tumor of the kidney, an entity completely distinct from Wilms tumor, by Garvin et al [38] . which may simply be due to the degree of FAK phosphorylation. These findings could also be explained by the idea of oncogene addiction. Investigators have postulated that certain tumor cell lines are physiologically more dependent upon specific survival factors, and inhibition of these specific cellular factors will have a more profound effect upon those cells than others even of the same tumor type [40] .
The small molecule FAK inhibitor, PF-573,228 was utilized in these studies to corroborate the siRNA findings that FAK was an important survival signal and a potential target in these rare and difficult to treat renal tumors. PF-573,228 has been shown to block the catalytic activity of FAK by binding to the ATP pocket of FAK [24] .
This molecule has been noted to decrease cell survival, migration and invasion in neuroblastoma cell lines [15] as well as decrease metastatic potential of breast cancer cells [41] and enhance chemotherapy-induced cytotoxicity in pancreatic cancer cell lines [42] . Realizing that off-target effects are a risk when using small molecule inhibitors, PF-573,226 was chosen over a similar FAK inhibitor, PF-562,271, in an effort to minimize off-target effects. PF-562,271, in addition to inhibiting FAK, also affects PyK2 [43] , which PF-573,228 does not. In this study, PF-573,226 effectively diminished FAK phosphorylation and increased cell death in both the G401 and SK-NEP-1 cell lines.
Additionally, this inhibitor also diminished the migration and invasion of the G401 cells at concentrations below the LD 50 for the cells. 
these tumors. Y15 has been previously described in the literature [17] and has been employed for FAK inhibition in vitro [15, 17, 18, 27] . Y15 is also one of only a few small molecule FAK inhibitors available to use in animal studies [17, 19, 27] . In a mouse xenograft model using BT474 human breast cancer cells, animals treated with Y15 (30 mg/kg/day) had significantly smaller tumors than vehicle treated animals [17] . The addition of Y15 to gemcitabine treatment was shown to have an additive affect on survival in a nude mouse model of pancreatic cancer [18] . In another pediatric solid tumor, neuroblastoma, Y15-induced FAK inhibition resulted in a significant decrease in both flank xenograft tumor growth [19] and in liver metastases [27] . These studies 
profound decrease in the volumes of the primary renal tumors, but no significant effect upon the presence of pulmonary metastases [45] .
The small molecules PF-573,228 and Y15 have been reported to inhibit FAK phosphorylation at the Y397 autophosphorylation site [17, 24] and that is why they were chosen for these investigations. Many consider the FAK autophosphorylation site (Y397) to play the primary role in how FAK affects tumor cell migration, invasion and survival. In our study, we did see inhibition of FAK Y397 phosphorylation in both cell lines ( Figure 3A and Figure 4A ), but at higher concentrations of the inhibitors there was also some inhibition of total FAK expression in both cell lines ( Figure 3A and Figure 4A ).
Other investigators have reported similar findings in other cell lines. Huanwen and colleagues found that pancreatic cancer cells treated with PF-573,228 had a decrease in total FAK expression following treatment with 10 μM concentration [42] . Similar results were noted when colon cancer cells were treated with PF-573,228 [46] . Y15 treatment of the human pancreatic cell line, Panc 1, led to a decrease in FAK phosphorylation but also decreased total FAK at higher concentrations [18] . Findings were similar in BT474 breast cancer cells [17] and U87 glioma cells [47] treated with Y15, in that, increasing concentrations of the inhibitor and also increasing the time of treatment resulted in decreased total FAK expression [17] .
In summary, we showed that FAK abrogation, using siRNA and small molecules, had a significant affect upon the malignant phenotype of G401 and SK-NEP-1 cells.
There was a significant decrease in cell survival, increased cellular apoptosis and decreased migration and invasion. An important observation was that the changes in 
E.
Immunoblots from a number of xenograft specimens were analyzed with densitometry.
Phosphorylated FAK was expressed as a ratio to total FAK for each blot and normalized to the β-actin for that blot, allowing for a comparison to be made between the saline treated and the Y15 treated tumors. There was a significant decrease in the FAK phosphorylation (Y397) in the tumors from the animals treated with Y15. 
